Eris Lifesciences Limited

NSEI:ERIS Stock Report

Market Cap: ₹186.0b

Eris Lifesciences Management

Management criteria checks 4/4

We currently do not have sufficient information about the CEO.

Key information

Amit Bakshi

Chief executive officer

₹48.8m

Total compensation

CEO salary percentage35.9%
CEO tenure17.8yrs
CEO ownership42.9%
Management average tenure8.2yrs
Board average tenure4.1yrs

Recent management updates

Eris Lifesciences Limited's (NSE:ERIS) CEO Compensation Looks Acceptable To Us And Here's Why

Sep 19
Eris Lifesciences Limited's (NSE:ERIS) CEO Compensation Looks Acceptable To Us And Here's Why

Recent updates

Here's Why Eris Lifesciences (NSE:ERIS) Can Manage Its Debt Responsibly

Nov 21
Here's Why Eris Lifesciences (NSE:ERIS) Can Manage Its Debt Responsibly

Eris Lifesciences Limited Just Missed EPS By 8.6%: Here's What Analysts Think Will Happen Next

Oct 30
Eris Lifesciences Limited Just Missed EPS By 8.6%: Here's What Analysts Think Will Happen Next

A Look At The Fair Value Of Eris Lifesciences Limited (NSE:ERIS)

Oct 15
A Look At The Fair Value Of Eris Lifesciences Limited (NSE:ERIS)

Eris Lifesciences Limited's (NSE:ERIS) CEO Compensation Looks Acceptable To Us And Here's Why

Sep 19
Eris Lifesciences Limited's (NSE:ERIS) CEO Compensation Looks Acceptable To Us And Here's Why

Earnings Tell The Story For Eris Lifesciences Limited (NSE:ERIS) As Its Stock Soars 27%

Sep 03
Earnings Tell The Story For Eris Lifesciences Limited (NSE:ERIS) As Its Stock Soars 27%

Earnings Update: Eris Lifesciences Limited (NSE:ERIS) Just Reported Its First-Quarter Results And Analysts Are Updating Their Forecasts

Aug 05
Earnings Update: Eris Lifesciences Limited (NSE:ERIS) Just Reported Its First-Quarter Results And Analysts Are Updating Their Forecasts

Eris Lifesciences (NSE:ERIS) Seems To Use Debt Quite Sensibly

Aug 04
Eris Lifesciences (NSE:ERIS) Seems To Use Debt Quite Sensibly

Estimating The Intrinsic Value Of Eris Lifesciences Limited (NSE:ERIS)

Jul 13
Estimating The Intrinsic Value Of Eris Lifesciences Limited (NSE:ERIS)

Eris Lifesciences Limited (NSE:ERIS) Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock?

May 24
Eris Lifesciences Limited (NSE:ERIS) Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock?

Why We're Not Concerned About Eris Lifesciences Limited's (NSE:ERIS) Share Price

May 10
Why We're Not Concerned About Eris Lifesciences Limited's (NSE:ERIS) Share Price

An Intrinsic Calculation For Eris Lifesciences Limited (NSE:ERIS) Suggests It's 25% Undervalued

Mar 14
An Intrinsic Calculation For Eris Lifesciences Limited (NSE:ERIS) Suggests It's 25% Undervalued

Analyst Estimates: Here's What Brokers Think Of Eris Lifesciences Limited (NSE:ERIS) After Its Third-Quarter Report

Feb 15
Analyst Estimates: Here's What Brokers Think Of Eris Lifesciences Limited (NSE:ERIS) After Its Third-Quarter Report

Earnings Tell The Story For Eris Lifesciences Limited (NSE:ERIS)

Dec 28
Earnings Tell The Story For Eris Lifesciences Limited (NSE:ERIS)

Eris Lifesciences (NSE:ERIS) Seems To Use Debt Quite Sensibly

Dec 07
Eris Lifesciences (NSE:ERIS) Seems To Use Debt Quite Sensibly

Are Eris Lifesciences Limited (NSE:ERIS) Investors Paying Above The Intrinsic Value?

Nov 11
Are Eris Lifesciences Limited (NSE:ERIS) Investors Paying Above The Intrinsic Value?

Are Eris Lifesciences Limited (NSE:ERIS) Investors Paying Above The Intrinsic Value?

Jul 20
Are Eris Lifesciences Limited (NSE:ERIS) Investors Paying Above The Intrinsic Value?

Does Eris Lifesciences (NSE:ERIS) Have A Healthy Balance Sheet?

Nov 20
Does Eris Lifesciences (NSE:ERIS) Have A Healthy Balance Sheet?

These 4 Measures Indicate That Eris Lifesciences (NSE:ERIS) Is Using Debt Safely

Jun 20
These 4 Measures Indicate That Eris Lifesciences (NSE:ERIS) Is Using Debt Safely

A Look At The Fair Value Of Eris Lifesciences Limited (NSE:ERIS)

Feb 24
A Look At The Fair Value Of Eris Lifesciences Limited (NSE:ERIS)

Is Now The Time To Put Eris Lifesciences (NSE:ERIS) On Your Watchlist?

Dec 28
Is Now The Time To Put Eris Lifesciences (NSE:ERIS) On Your Watchlist?

Here's Why I Think Eris Lifesciences (NSE:ERIS) Might Deserve Your Attention Today

Sep 23
Here's Why I Think Eris Lifesciences (NSE:ERIS) Might Deserve Your Attention Today

If You Like EPS Growth Then Check Out Eris Lifesciences (NSE:ERIS) Before It's Too Late

May 26
If You Like EPS Growth Then Check Out Eris Lifesciences (NSE:ERIS) Before It's Too Late

Eris Lifesciences Limited (NSE:ERIS) Shares Could Be 34% Above Their Intrinsic Value Estimate

Apr 17
Eris Lifesciences Limited (NSE:ERIS) Shares Could Be 34% Above Their Intrinsic Value Estimate

Eris Lifesciences Limited's (NSE:ERIS) Stock Has Fared Decently: Is the Market Following Strong Financials?

Mar 12
Eris Lifesciences Limited's (NSE:ERIS) Stock Has Fared Decently: Is the Market Following Strong Financials?

Does Eris Lifesciences (NSE:ERIS) Deserve A Spot On Your Watchlist?

Feb 25
Does Eris Lifesciences (NSE:ERIS) Deserve A Spot On Your Watchlist?

Why Eris Lifesciences Limited (NSE:ERIS) Is A Dividend Rockstar

Feb 12
Why Eris Lifesciences Limited (NSE:ERIS) Is A Dividend Rockstar

Eris Lifesciences Limited (NSE:ERIS) Analysts Are Pretty Bullish On The Stock After Recent Results

Jan 30
Eris Lifesciences Limited (NSE:ERIS) Analysts Are Pretty Bullish On The Stock After Recent Results

Read This Before Buying Eris Lifesciences Limited (NSE:ERIS) Shares

Jan 17
Read This Before Buying Eris Lifesciences Limited (NSE:ERIS) Shares

Our View On Eris Lifesciences' (NSE:ERIS) CEO Pay

Dec 30
Our View On Eris Lifesciences' (NSE:ERIS) CEO Pay

CEO Compensation Analysis

How has Amit Bakshi's remuneration changed compared to Eris Lifesciences's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

₹3b

Jun 30 2024n/an/a

₹4b

Mar 31 2024₹49m₹17m

₹4b

Dec 31 2023n/an/a

₹4b

Sep 30 2023n/an/a

₹4b

Jun 30 2023n/an/a

₹4b

Mar 31 2023₹49m₹17m

₹4b

Dec 31 2022n/an/a

₹4b

Sep 30 2022n/an/a

₹4b

Jun 30 2022n/an/a

₹4b

Mar 31 2022₹46m₹26m

₹4b

Dec 31 2021n/an/a

₹4b

Sep 30 2021n/an/a

₹4b

Jun 30 2021n/an/a

₹4b

Mar 31 2021₹27m₹27m

₹4b

Dec 31 2020n/an/a

₹3b

Sep 30 2020n/an/a

₹3b

Jun 30 2020n/an/a

₹3b

Mar 31 2020₹49m₹18m

₹3b

Dec 31 2019n/an/a

₹3b

Sep 30 2019n/an/a

₹3b

Jun 30 2019n/an/a

₹3b

Mar 31 2019₹49m₹18m

₹3b

Dec 31 2018n/an/a

₹3b

Sep 30 2018n/an/a

₹3b

Jun 30 2018n/an/a

₹3b

Mar 31 2018₹49m₹11m

₹3b

Compensation vs Market: Amit's total compensation ($USD577.27K) is about average for companies of similar size in the Indian market ($USD503.20K).

Compensation vs Earnings: Amit's compensation has been consistent with company performance over the past year.


CEO

Amit Bakshi (49 yo)

17.8yrs

Tenure

₹48,776,648

Compensation

Mr. Amit Indubhushan Bakshi serves as Chairman and Managing Director at Eris Lifesciences Limited. Mr. Bakshi has an extensive experience of Indian Pharmaceutical industry and handles Strategic Management...


Leadership Team

NamePositionTenureCompensationOwnership
Amit Bakshi
Chairman & MDno data₹48.78m42.86%
₹ 79.7b
Sachin Shah
Chief Financial Officer8.2yrs₹18.01mno data
Krishnakumar Vaidyanathan
Executive Director & COO3.5yrs₹44.85mno data
Gagan Atreja
President of Sales & Marketingno data₹22.05mno data
Inderjeet Negi
Executive Directorno data₹12.40m4.36%
₹ 8.1b
Kaushal Shah
Whole Time Directorno data₹6.99m3.28%
₹ 6.1b
Deepak Kapoor
Senior Vice Presidentno data₹13.72mno data
Milind Talegaonkar
Compliance Officer & Company Secretary8.2yrsno datano data
Vijay Joshi
President Medicalno data₹12.31mno data
Manish Kapoor
Vice Presidentno data₹12.36mno data
Alok Mahajan
Vice Presidentno data₹13.30mno data
Viraj Suvarna
Vice Presidentno data₹15.08mno data

8.2yrs

Average Tenure

50yo

Average Age

Experienced Management: ERIS's management team is seasoned and experienced (8.2 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Amit Bakshi
Chairman & MD17.8yrs₹48.78m42.86%
₹ 79.7b
Krishnakumar Vaidyanathan
Executive Director & COO3.9yrs₹44.85mno data
Inderjeet Negi
Executive Director17.8yrs₹12.40m4.36%
₹ 8.1b
Kaushal Shah
Whole Time Director4.3yrs₹6.99m3.28%
₹ 6.1b
Prashant Gupta
Independent Non-Executive Director6.6yrs₹4.13mno data
Sujesh Vasudevan
Independent Non-Executive Director2.3yrs₹4.05mno data
Kalpana Unadkat
Independent Non-Executive Director3.8yrs₹4.51mno data
Rajeev Dalal
Independent Non-Executive Director3.9yrs₹4.65mno data

4.1yrs

Average Tenure

50yo

Average Age

Experienced Board: ERIS's board of directors are considered experienced (4.1 years average tenure).